LEO Pharma announces more than half of patients on Kyntheum® (brodalumab) maintain consistent levels of complete skin clearance for more than two years
NOT FOR DISTRIBUTION IN THE UNITED STATES
LEO Pharma today announced new Phase III data broadening the evidence base for the efficacy, safety and quality of life benefits of Kyntheum ® (brodalumab), a biologic treatment for people with moderate-to-severe plaque psoriasis. Results from a long-term extension study found Kyntheum® provided sustained high levels of skin clearance (PASII 100) over more than two years in those with moderate-to-severe disease.1 Separate pooled analyses from the AMAGINE clinical trials showed that patients receiving Kyntheum® reported significant health-related quality of life improvements versus placebo.2,3 These data were presented at the 26th European Academy of Dermatology (EADV) annual congress in Geneva, Switzerland.
Psoriasis is a serious, lifelong condition impacting emotional, psychological and physical health. Although its systemic nature often remains unrecognised, people living with psoriasis are at an increased risk of developing serious associated conditions, which further impact quality of life.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.5 For these reasons, lasting skin clearance of symptoms and plaques is an important treatment goal, especially for those with the most severe forms of the disease.5
Results from the AMAGINE-2 extension study confirmed Kyntheum® was able to deliver completely clear skin (PASI 100) in more than half of patients (56.2%, n=779) and almost clear skin (PASI 90) in more than three-quarters of patients (76.8%, n= 779) after two years (120 weeks) of treatment.1 The proportions of patients achieving high levels of skin clearance were comparable to results at year one (week 52) (with 53% and 78% of patients achieving PASI 100 and PASI 90, in year one respectively).1 At week 120, Kyntheum® continued to be well-tolerated with a comparable safety profile, as observed in the 52-week study.1 The most common adverse events were nasopharyngitis (inflammation of the nose and pharynx), upper respiratory tract infection, arthralgia (joint pain), and headache.1
“These new data are encouraging as they demonstrate the potential long-term efficacy and safety of Kyntheum ® and reinforce its ability to provide psoriasis patients with high levels of lasting skin clearance. It is important that people with moderate-to-severe plaque psoriasis have treatment options that help them to not only achieve clear, healthy skin, but also the capability to relieve the substantial burden the disease places on patients’ everyday lives,” commented Professor Dr. Ulrich Mrowietz, Psoriasis Centre, University Medical Centre, Schleswig-Holstein, Germany.
The burden of psoriasis on quality of life is comparable to other chronic conditions like diabetes and heart diseases.6 Measuring improvements in health-related quality of life is important as they reflect a patient’s experience or perception of disease impact, which is not evaluated by PASI scores alone.7
New pooled analyses of the Phase III AMAGINE(-1,-2,-3) studies showed that significantly greater improvements in health-related quality of life were experienced with Kyntheum® compared with placebo, as measured by the Dermatology Life Quality Index (DLQI)II questionnaire.2,3 At week 12, 59% of Kyntheum® patients reported psoriasis had no impact on their overall quality of life compared to 6% of patients on placebo.3 This was experienced specifically with significant improvements across daily/leisure activities, as well as work/school lives.2 Furthermore, at week 12, 43% of Kyntheum® patients were no longer embarrassed or self-conscious about their psoriasis.3
“Psoriasis is not just a skin condition and the full impact of the disease is often underestimated,” said Gitte Pugholm Aabo, President and CEO, LEO Pharma. “At LEO Pharma we are dedicated to supporting patients with innovative treatment solutions such as Kyntheum ® that can help patients live a more positive life, clear of their skin condition.”
Kyntheum® was granted marketing authorisation by the European Commission in July 20178 and is the first and only biologic that selectively targets the IL-17 receptor subunit A.9,10 By binding to this specific receptor on the cells of the skin, rather than targeting free inflammatory mediators, Kyntheum® blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are involved in psoriasis plaque formation.10,11,12 This mechanism of action is different to all other psoriasis biologics currently available.10,13
A total of 16 Kyntheum® abstracts are being presented at the 2017 EADV annual congress.
NOTES TO EDITORS
About Kyntheum ®
Kyntheum® (brodalumab) is the only fully human monoclonal antibody that selectively targets the IL-17 receptor subunit A.10,13 By binding to the receptor with high affinity, Kyntheum® effectively blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are important in psoriasis.ý13,14
The psoriasis clinical studies programme for Kyntheum® consisted of three clinical trials; AMAGINE-1 (n=661), AMAGINE-2 (n=1831) and AMAGINE-3 (n=1881).15,16 Results showed Kyntheum® 210mg offered more patients complete skin clearance (PASI 100) at 12 weeks compared to patients treated with ustekinumab [AMAGINE-2: 44% (n=272) versus 22% (n=65), p<0.001; AMAGINE-3: 37% (n=229) versus 19% (n=58), p<0.001].15
In AMAGINE-1 83% of patients on Kyntheum® 210mg achieved PASI 75 compared to 3% of patients treated with placebo at 12 weeks [83.3% (n=185) versus 2.7% (n=6), p<0.001] and 76% of patients achieved sPGAIII success versus 1% of patients treated with placebo [75.7% (n=168) versus 1.4% (n=3), p<0.001].16
In the AMAGINE trials more than half (53-56%) of patients on continuous Kyntheum® treatment achieved PASI 100 at week 52.16,17
Patients also reported experiencing improved health-related quality of life after four weeks of treatment with Kyntheum®.18 After 12 weeks of treatment, seven in 10 patients (72%, n=29/40, p<0.0001) reported psoriasis no longer impaired their health-related quality of life, (0/1 DLQI) compared with placebo (5%, n=2/37).18
Data from the three large randomised, controlled AMAGINE clinical trials, found Kyntheum® to be well tolerated, with an acceptable safety profile.19 The most common adverse events were arthralgia (joint pain), headache, fatigue, diarrhoea and oropharyngeal (mouth and throat) pain.16
In July 2016, LEO Pharma entered into a partnership agreement with AstraZeneca granting LEO Pharma exclusive licence to develop and commercialise Kyntheum® in Europe.IV Outside of Europe, Valeant Pharmaceuticals has global commercial rights for brodalumab except in Japan and certain other Asian countries, where the rights are held by Kyowa Hakko Kirin Co. Ltd.
Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin.5 The most frequently reported symptoms include thickening and scaling of the skin, itching and erythema (superficial reddening of the skin, usually in patches).5
An estimated 125 million people worldwide live with psoriasis,20 including nearly 14 million Europeans.21
Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person’s life.22 People with psoriasis, especially those with more severe symptoms, are also at increased risk of developing other serious associated conditions,4 including heart disease23,24,25 and metabolic diseases (a combination of diabetes, high blood pressure and obesity).26 Mental health complications, such as depression and anxiety, are also more common in people with psoriasis.27
According to the World Health Organization, the burden of living with psoriasis is underestimated and it urges for action to fight stigma and improve treatment.5
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. LEO Pharma offers a comprehensive range of integrated care solutions for control and relief of psoriasis. By expanding its portfolio into biologics, through the approval of Kyntheum®, the company is set to become the world’s leading dermatology company.
Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.
For more information, visit www.leo-pharma.com
Subscribe to our YouTube channel: www.youtube.com/leopharmaglobal
Follow us on Twitter: www.twitter.com/leohealthyskin
Visit us at LinkedIn: www.linkedin.com/company/leo-pharma
I The Psoriasis Area and Severity Index (PASI) score is used in clinical trials to indicate a % change in disease, i.e. PASI 75 is defined as the proportion of patients that reach ≥ 75% improvement in Psoriasis Area and Severity Index score. PASI 90 or PASI 100 indicates patients who have achieved almost clear or complete skin clearance
II The Dermatology Life Quality Index (DLQI), is a tool commonly used by Dermatologists to assess the quality of life impact of skin disease across areas such as work and social activities as well as symptoms and patients’ feelings about their condition. The data presented at EADV refers to responses to specific sections of this overall DLQI questionnaire.
III sPGA success is defined as patients who achieved a static Physician’s Global Assessment 0 or 1
IV Kyntheum® is not approved by Swissmedic for marketing in Switzerland.
1. Lebwohl M, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1790
2. Mrowietz U, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1791
3. Mrowietz U, et al. European Academy of Dermatology and Venereology annual congress 2017. Poster P1792
4. Reich K. Eur Acad Dermatol Venereol. 2012; 26(2):3-11
5. World Health Organization (WHO). Global Report on Psoriasis. Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf (Accessed September 2017)
6. Rapp SR, et al. J Am Acad Dermatol 1999;41:401-407
7. Grob JJ. J Invest Dermatol. 2007;127:2299-2301
8. European Medicines Agency, European public assessment report, Kyntheum® (brodalumab). Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003959/human_med_002054.jsp&mid=WC0b01ac058001d124 (Accessed September 2017)
9. Kyntheum®. Summary of Product Characteristics. 2017
10. Campa M, et al. Dermatol Ther. 2016;6:1–12
11. Beringer A, et al. Trends Mol Med. 2016; 22: 230-41
12. Russell CB, et al. J Immunol. 2014; 192: 3828-36
13. Coimbra S, et al. Core Evidence. 2014;9:89-97
14. Papp K, et al. N Engl J Med 2012;336:1181-9
15. Lebwohl M, et al. N Engl J Med. 2015;373:1318-28
16. Papp K, et al. Br J Dermatol. 2016;175:273–286
17. Supplement to: Lebwohl M, et al. N Engl J Med. 2015;373:1318-28
18. Gordon KB, et al. Br J Dermatol. 2014;170:705–15
19. Attia A, et al. Clin Drug Investig. 2017; DOI: 10.1007/s40261-017-0500-9
20. The International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com/ (Accessed September 2017)
21. Ortonne J, et al. Eur J Dermatol. 2004;14:41–45
22. National Institute for Health and Care Excellence (NICE) Psoriasis: assessment and management guidelines. Available at: https://www.nice.org.uk/guidance/cg153/chapter/1-Guidance#systemic-therapy (Accessed September 2017)
23. Gelfand JM, et al. JAMA. 2016;296:1735-41
24. Ahlehoff O, et al. Eur Heart J. 2012;33:2054-64
25. Lowes MA, et al. Ann Rev Immunol. 2014;32:227-35
26. Langan SM, et al. J Invest Dermatol. 2012 Mar; 132(3 0 1): 556–562
27. Dalgard F, et al. JID. 2015;135(4), 984-991
Global media contacts
Henrik Steen Heskjær Kyndlev
Head of Global External Communication
Mobile: +45 3140 6180
Marie Schleimann Nordlund
Snr Global Patient Communication Manager
Mobile: +45 3126 3734
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Saif bin Zayed Inaugurates Interfaith Alliance for Safer Communities: Child Dignity in the Digital World Forum19.11.2018 21:13 | Pressemelding
Held under the patronage of His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, Lt. General HH Sheikh Saif bin Zayed Al Nahyan, Deputy Prime Minister and Minister of Interior, officially launched the inaugural edition of the Interfaith Alliance for Safer Communities: Child Dignity in the Digital World Forum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005843/en/ Lt. General HH Sheikh Saif bin Zayed Al Nahyan, Deputy Prime Minister and Minister of Interior (Photo: AETOSWire) The two-day assembly is hosted by the UAE on November 19-20 in recognition of the country’s leading role in promoting tolerance and interfaith dialogue. In his speech at the opening ceremony, His Highness Sheikh Saif said: “We are gathered here today under the umbrella of peace, coexistence and tolerance; an approach that was inspired by the ideology, legacy and directi
Synacor Zimbra Deployments up as Customers Adopt Latest Collaboration Capabilities19.11.2018 20:53 | Pressemelding
Synacor Inc. (NASDAQ: SYNC) today announced its Zimbra open source-based collaboration platform for email, calendaring, messaging and more continues to see expanded global adoption. Following the release of Zimbra 8.8, business and government customers are ramping up on Zimbra to take advantage of critical data privacy and security, open source flexibility, and low total cost of ownership. More than 80 new customers deployed Zimbra around the world in Q3, across sectors including education, retail and government, bringing the 2018 Zimbra new customer tally to 310. Grupo BC, a business process outsourcing leader, based in Europe and Latin America, is among the latest to deploy Zimbra 8.8. “Grupo BC is in growth mode, and as we rapidly expand into new countries, email and collaboration security is a priority,” said Francesc Genové, IT Director, Grupo BC. “Zimbra Network Edition addresses our increasing communications requirements with the flexibility we need to do more business in more p
Pacific Drilling Successfully Emerges from Chapter 11 Proceedings19.11.2018 20:18 | Pressemelding
Pacific Drilling S.A. (OTC: PACDQ) (the “Company”) announced that effective today the Company and certain of its affiliated chapter 11 debtors have emerged from bankruptcy after successfully completing restructuring transactions pursuant to their chapter 11 plan of reorganization (the “Plan”). In connection with emergence from bankruptcy, the Company raised $1.5 billion in gross proceeds in new capital, consisting of $1.0 billion of new secured notes and $500 million of equity. Pursuant to the Plan, the Company equitized approximately $1.85 billion in pre-petition debt associated with the Company’s Term Loan B, 2017 Notes and 2020 Notes, and paid in full approximately $1.2 billion of debt related to its pre-petition senior secured credit facility, revolving credit facility and the post-petition debtor-in-possession financing. Customer, employee and ordinary trade claims were unimpaired. The Plan has strengthened the Company’s balance sheet by significantly reducing its leverage and enh
Tempo Announces New Majority Ownership by Diversis Capital19.11.2018 20:10 | Pressemelding
Tempo, a leader in productivity-enhancing project management solutions, today welcomes Diversis Capital as a new strategic owner with a controlling interest in the company. Former owner and founder, Origo, will retain a 45% stake in Tempo, and remains an important partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181119005782/en/ “We are very pleased to announce new ownership by Diversis Capital with their wide experience of working with unique tech companies and the tremendous opportunity for growth that this brings,” said Agust Einarsson, CEO of Tempo. “Diversis has demonstrated their value to investments through its collaborative approach using their operating partner and strategic advisors working alongside management to take companies to the next level. Additional financial support will lend further strength to Tempo’s global growth.” Created in 2007 as an internal tool to track time utilization and management on
Valence Advises Golden Gate on Acquisition of Active Minerals19.11.2018 19:07 | Pressemelding
The Valence Group acted as financial advisor to Golden Gate Capital on its announced acquisition of Active Minerals International from Merit Capital Partners. Financial terms of the transaction were not disclosed. About Active Minerals International Active Minerals International LLC (AMI) is a worldwide leader in the production and marketing of kaolin and gel quality attapulgite clay minerals. Its products are sold throughout the world for industrial, agricultural and construction related applications. AMI is the world’s largest supplier of gel quality attapulgite (clay) and is the largest supplier of air-float kaolin to the glass manufacturing process. About Golden Gate Capital Golden Gate Capital is a San Francisco-based private equity investment firm with over $15 billion of capital under management. The principals of Golden Gate Capital have a long and successful history of investing across a wide range of industries and transaction types, including going-privates, corporate divest
Moody’s Analytics Earns #4 Spot in 2019 Chartis RiskTech100®19.11.2018 16:45 | Pressemelding
Moody’s Analytics, a global provider of financial intelligence, has been ranked #4 in the 2019 Chartis RiskTech100®, our best-ever finish. We also won awards in the Strategy category and in five solution categories: CECL, IFRS 9, Balance Sheet Risk Management, Credit Risk for the Banking Book, and Model Validation. This year, Moody’s Analytics earned a category award in one of the overall Chartis categories, Strategy, which considered our ability to execute, our vision and leadership, and our financial performance. Click here for more on our solution category wins. Now in its 13th year, the RiskTech100® evaluates technology companies that provide risk and compliance solutions to financial institutions. Moody’s Analytics has finished in the top five of these rankings for three straight years. “Moody’s Analytics continues to help its clients across the globe to satisfy their risk technology needs,” said Rob Stubbs, Head of Research at Chartis Research. “The breadth of its offerings is re